## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%); PEG 2.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 1)

**1. GE HealthCare, Mayo Clinic launch digital twin project for personalizing radiation cancer therapy**
- Source: Fierce Biotech | 20251204T170854 | Bullish | Relevance: 100%
- GE HealthCare and the Mayo Clinic are collaborating on GEMINI-RT, a project to develop personalized radiation therapy for cancer patients using AI digital twins. This initiative will integrate imaging, AI, and patient monitoring to automate radiation dose planning, predict treatment outcomes, and incorporate remote monitoring for side effects. The goal is to create tailored treatments by modeling individual patient journeys.

**2. GE HealthCare Technologies Inc. stock falls Thursday, underperforms market**
- Source: MarketWatch | 20251204T165600 | Bearish | Relevance: 100%
- GE HealthCare Technologies Inc. (GEHC) saw its stock price decline by 1.28% to $82.52 on Thursday. This performance was in contrast to the broader market, as the S&P 500 Index rose, while the Dow Jones Industrial Average experienced a slight dip. The stock's fall ended a two-day winning streak for the company.

**3. GE HealthCare, Mayo Clinic collab on radiation therapy, advanced cancer care**
- Source: MassDevice | 20251204T134100 | Bullish | Relevance: 100%
- GE HealthCare and Mayo Clinic have announced a new collaboration called GEMINI-RT to transform personalized radiation therapy and cancer care. This initiative builds on previous collaborations and aims to innovate in prediction, planning, automation, workflow, and monitoring in radiation oncology. The partnership will focus on integrating imaging, advanced therapies, and data-driven solutions to deliver comprehensive, personalized care for cancer patients.

**4. GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy and advanced cancer care**
- Source: BioSpace | 20251204T101737 | Bullish | Relevance: 100%
- GE HealthCare and Mayo Clinic have launched GEMINI-RT, an initiative to personalize radiation therapy through the integration of imaging, AI, and patient monitoring. This collaboration focuses on automation, predictive oncology, multi-modal therapies, and connected care to enhance clinical outcomes and streamline cancer treatment. The research aims to "twin the patient" by creating precise models of individual patient journeys, enabling tailored radiation therapy.

**5. GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy a**
- Source: PharmiWeb.com | 20251203T220744 | Bullish | Relevance: 100%
- GE HealthCare and Mayo Clinic have launched GEMINI-RT, a research collaboration aimed at transforming personalized radiation therapy and cancer care. The initiative integrates imaging, AI, and patient monitoring, focusing on four key pillars: automation, predictive oncology, multi-modal therapies, and outpatient monitoring. This collaboration seeks to enhance clinical outcomes, reduce clinician burnout, and accelerate innovation in radiation oncology.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.50 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.2B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.50 |
| Forward P/E | 16.7 |
| Current P/E | 18.1 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.9% to 1.7% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.87), confirming momentum. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.72% (CS: 69) | Neutral |
| RSI_14 | 66.2 | Neutral |
| MACD Histogram | 0.87 | Bullish |
| vs SMA20 | 1.082x | Above |
| vs SMA50 | 1.093x | Above |
| vs SMA200 | 1.104x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $82.52
- **Stop Loss:** $78.10 (5.4% risk)
- **Target:** $86.94 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 113
- **Position Value:** $9,324.76
- **Portfolio %:** 9.32%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*